Andy Murdock

Researchers at UC Berkeley and UCSF’s  Innovative Genomics Institute, or IGI, have found the diversity of CRISPR gene editors in viruses goes far beyond what they expected, possibly leading to new ways of editing genomes. 

CRISPR genome editing technology, which was developed at UC Berkeley, has been approved for clinical trials to correct gene mutations responsible for sickle cell disease.

Amid a surge in COVID-19 cases and the detection of new variants of the virus on campus, the Innovative Genomics Institute, or IGI, at UC Berkeley aims to sequence viral genomes to improve student safety.

UC Berkeley's Innovative Genomics Institute, or IGI's, Free Asymptomatic Saliva Test, or FAST, study for COVID-19 will end Thursday after having tested more than 4,800 people, according Jennifer Doudna, president and chair of the IGI governance board

Jennifer Doudna, UC Berkeley professor of chemistry, biochemistry and molecular biology, was awarded half of the Nobel Prize in chemistry Wednesday for developing the gene-editing technology CRISPR-Cas9.